E. Cohen

发表

Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.

D. Nelson, H. Wedemeyer, G. Foster, 2017, Journal of hepatology.

Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein.

S. Wadler, M. Schwartz, A. Siegel, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of progression‐free survival in patients presenting with hepatocellular carcinoma within the Milan criteria

M. Valsecchi, M. Strazzabosco, L. Antolini, 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Outcomes after combined liver–kidney transplant vs. kidney transplant followed by liver transplant

S. Jensik, J. Perkins, R. Bhattacharya, 2015, Clinical transplantation.

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)

T. Pilot‐Matias, G. Foster, K. Agarwal, 2018, Journal of viral hepatitis.

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial.

M. Buti, M. Burroughs, E. Zuckerman, 2020, Journal of hepatology.

Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials

D. Cohen, R. Menon, E. Cohen, 2018, European Journal of Clinical Pharmacology.

Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection.

B. Bacon, D. Nelson, E. Tapper, 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.

K. Reddy, D. Bernstein, M. Sulkowski, 2016, Gastroenterology.

Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.

M. Hertl, E. Cohen, G. A. Singer, 2015, Transplantation proceedings.

Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with HCV Genotype-Infection who Failed a Prior Course of DAA Therapy: The Quartz-I Study

T. Pilot‐Matias, G. Everson, D. Cohen, 2016 .

LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study

K. Reddy, D. Bernstein, M. Sulkowski, 2015 .

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease

K. Reddy, T. Hassanein, K. Agarwal, 2018, Kidney international reports.

Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct‐acting antiviral therapy

T. Pilot‐Matias, G. Everson, D. Cohen, 2019, Journal of medical virology.